mouse monoclonal anti cd209 antibody  (R&D Systems)

Journal: iScience

Article Title: Macrophages treated with interferons induce different responses in lymphocytes via extracellular vesicles

doi: 10.1016/j.isci.2024.109960

Figure Lengend Snippet:

Article Snippet: Mouse monoclonal anti CD209/DC-SIGN (clone REA617) Conjugated APC , Miltenyi , Cat#130-124-257.

Techniques: Recombinant, Protein Extraction, Protease Inhibitor, Pore Size, Electrophoresis, Staining, Software, Cytometry

Journal: International journal of molecular sciences

Article Title: Analysis of CD1a-Positive Monocyte-Derived Cells in the Regional Lymph Nodes of Patients with Gallbladder Cancer.

doi: 10.3390/ijms252312763

Figure Lengend Snippet: Figure 2. Representative images of immunohistochemistry of CD209 (DC-SIGN) ((a) original mag- nification ×100, (b) original magnification ×200). (a) Many CD209-positive cells are found at the sinuses of LNs. (b) In metastatic LNs, CD209-positive cells are found at stroma surrounding cancer cells, some of them having dendritic shapes. (c) Image of immunohistochemistry of CD1a, almost the same area of (b). Dendritic-shaped CD1a-positive cells are found at stroma surrounding cancer cells (original magnification ×200).

Article Snippet: The following primary antibodies were used: the mouse monoclonal anti-CD1a antibody (clone 010; IS06930–2; prediluted; Dako, Glostrup, Denmark); the rabbit polyclonal antiS100 antibody (GA50461–2 J; prediluted; Dako); and the mouse monoclonal anti-CD209 antibody (clone 120507; R&D systems, Minneapolis, MN, USA).

Techniques: Immunohistochemistry

Journal: Frontiers in Immunology

Article Title: Proteus mirabilis Targets Atherosclerosis Plaques in Human Coronary Arteries via DC-SIGN (CD209)

doi: 10.3389/fimmu.2020.579010

Figure Lengend Snippet: Bacterial strains and cell lines used in this study.

Article Snippet: Anti-human DC-SIGN and anti-human Langerin monoclonal antibodies (MAbs) were purchased from Pharmingen (San Diego, CA, USA).

Techniques: Expressing, Transformation Assay, Plasmid Preparation, Isolation, Generated

Journal: Frontiers in Immunology

Article Title: Proteus mirabilis Targets Atherosclerosis Plaques in Human Coronary Arteries via DC-SIGN (CD209)

doi: 10.3389/fimmu.2020.579010

Figure Lengend Snippet: hDC-SIGN and hLangerin are receptors for the rough P. mirabilis. (a) P. mirabilis invades the CHO cell line that expresses hDC-SIGN and hLangerin. Y. pseudotuberculosis (Y1); E coli K-12 (CS180 and CS1861); P. mirabilis and P. mirabilis- pAY100.1 were examined for their ability to invade CHO/CHO-hDC-SIGN (A) and CHO/CHO-hLangerin cells (B) using the gentamicin protection assay. The number of phagocytosed bacteria was determined by counting the recovered CFUs. The data were pooled from three independent experiments. *** P < 0.001, **** P < 0.0001. b The interactions between P. mirabilis with CHO-hDC-SIGN and CHO-hLangerin were blocked by the anti-hDC-SIGN antibody, by mannan oligosaccharides by shielding the ligand of the LPS core by expressing the O-antigen. (C) P. mirabilis was incubated with CHO-hDC-SIGN for 2 h in the presence or absence of anti-hDC-SIGN and mannan. The phagocytosis rate of P. mirabilis was evaluated by recovering the bacteria from the gentamicin protection assay. E. coli K12 CS180 was used as the control strain to show the core LPS-dependent interaction with hDC-SIGN. (D) Anti-hLangerin and mannan were examined for their ability to inhibit the interaction between CHO-hLangerin and P. mirabilis . The data presented were pooled from three independent experiments. *** P < 0.001, **** P < 0.0001.

Article Snippet: Anti-human DC-SIGN and anti-human Langerin monoclonal antibodies (MAbs) were purchased from Pharmingen (San Diego, CA, USA).

Techniques: Expressing, Incubation

Journal: Frontiers in Immunology

Article Title: Proteus mirabilis Targets Atherosclerosis Plaques in Human Coronary Arteries via DC-SIGN (CD209)

doi: 10.3389/fimmu.2020.579010

Figure Lengend Snippet: All coronary arteries with plaques, but not healthy human arteries expressed DC-SIGN. Immunostaining for DC-SIGN and Langerin using the brown immunoperoxidase (DAB) technique was described in the materials and methods section. (A) DC-SIGN expression was detected in all human coronary plaques. (B) DC-SIGN expression was not detected in normal human arteries. (C) Langerin was expressed in one human coronary plaque. (D) Langerin was not expressed in normal human arteries. Magnification: ×200 in (A–D.)

Article Snippet: Anti-human DC-SIGN and anti-human Langerin monoclonal antibodies (MAbs) were purchased from Pharmingen (San Diego, CA, USA).

Techniques: Immunostaining, Expressing

Journal: Frontiers in Immunology

Article Title: Proteus mirabilis Targets Atherosclerosis Plaques in Human Coronary Arteries via DC-SIGN (CD209)

doi: 10.3389/fimmu.2020.579010

Figure Lengend Snippet: P. mirabilis interacts with atherosclerotic plaques, which was inhibited by the anti-hDC-SIGN antibody, mannan oligosaccharide, as well as by covering the ligand. A similar approach to Figure 4 , the arteries with atherosclerotic plaques were regarded as CHO-DC-SIGN, respectively. (A) The two sets of bacteria including E. coli K-12 strains (CS180 and CS1861), P. mirabilis , and P. mirabilis- pAY100.1 were incubated with atherosclerotic plaques to determine the adherence ability of the plaques. (B) P. mirabilis was incubated with atherosclerotic plaques for 2 h in the presence or absence of anti-hDC-SIGN, mannan, and core oligosaccharide from P. mirabilis . E. coli K12 CS180 was used as the control strains. The data were pooled from three independent experiments. *** P < 0.001, **** P < 0.0001.

Article Snippet: Anti-human DC-SIGN and anti-human Langerin monoclonal antibodies (MAbs) were purchased from Pharmingen (San Diego, CA, USA).

Techniques: Incubation